RxDoctor Payments DataLook up a doctor →

Christy Vath, PA

Physician Assistant · Seattle, WANPI 1427044510

Payments from drug & device makers

$74,569in general payments, 2019–2025

Across 908 payments — averaging $82.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$29K
  • UCB, Inc.$15K
  • Novartis$7K
  • Johnson & Johnson$5K
  • Amgen$4K
  • AbbVie$3K
  • plus $10K from 26 others

What the payments were for

  • Consulting fees$21,55429%
  • Speaking & faculty fees$27,02536%
  • Travel & lodging$6,6249%
  • Food & beverage$19,25426%
  • Education$1120%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$74,569 in reported general payments places this provider in the 95th percentile of 2,741 physician assistant providers in Washington.

See all physician assistant providers in Washington

Medicare billing

Part B allowed, 2024
$694,628
Medicare patients
176
Services billed
62,399

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab37$461,963
EnbrelEtanercept44$416,321
RinvoqUpadacitinib30$240,862
Orencia ClickjectAbatacept18$170,053
Xeljanz XrTofacitinib Citrate22$123,231
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5012$98,449
OrenciaAbatacept13$89,103
Hydroxychloroquine Sulfate139$4,892
MethotrexateMethotrexate Sodium185$4,280
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen36$2,632
Tramadol Hcl142$2,306
Prednisone204$2,228
Gabapentin62$2,140
Celecoxib49$1,845
Duloxetine Hcl67$1,763

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel$4,460$416,32144 claims
AbbVieRinvoq$3,366$240,86230 claims
E.r. Squibb & Sons, L.L.C.Orencia$1,503$89,10313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,741 physician assistant providers in Washington.

Other physician assistant in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →